Literature DB >> 33615747

Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: a population-based national cancer registry study.

Mee Joo Kang1, Jiwon Lim2, Sung-Sik Han1, Hyeong Min Park1, Sun-Whe Kim1, Young-Joo Won2,3, Sang-Jae Park1.   

Abstract

BACKGROUND: Misclassification of Klatskin tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). This study aimed to investigate the impact of misclassified Klatskin tumor on iBDC and eBDC incidences in Korea, where BDC is highly endemic.
METHODS: The data of incidence, topography and morphology code of BDC from 1999 to 2017 were obtained from the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin tumor was reclassified as eBDC.
RESULTS: Klatskin tumor accounted for 13.5% of all 81,414 BDC cases. In the registry, an average of 59.7% of Klatskin tumor was classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% overestimation of iBDC cases and a 15.0% underestimation of eBDC cases in average. After reclassification, age standardized rate (ASR) of incidence per 100,000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2. Average annual percent change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but ASR of iBDC significantly decreased since 2012 (p<0.0001).
CONCLUSIONS: Misclassification of Klatskin tumor has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Bile duct neoplasms; Cholangiocarcinoma; Epidemiology; Incidence; Klatskin tumor

Year:  2021        PMID: 33615747     DOI: 10.1002/jhbp.916

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  6 in total

1.  Epidemiology and future prediction of Korean liver, pancreatic and biliary cancer.

Authors:  Sung-Sik Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-06-30

2.  Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence.

Authors:  Hee Ju Sohn; Hongbeom Kim; Jae Ri Kim; Jae Sung Kang; Youngmin Han; Mirang Lee; Hyeong Seok Kim; Wooil Kwon; Suk Kyun Hong; YoungRok Choi; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jin-Young Jang
Journal:  Ann Surg Treat Res       Date:  2022-05-03       Impact factor: 1.766

3.  Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study.

Authors:  Mee Joo Kang; Jiwon Lim; Sung-Sik Han; Hyeong Min Park; Sun-Whe Kim; Woo Jin Lee; Sang Myung Woo; Tae Hyun Kim; Young-Joo Won; Sang-Jae Park
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

4.  Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019.

Authors:  Sung Yeon Hong; Mee Joo Kang; Taegyu Kim; Kyu-Won Jung; Bong-Wan Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-08-08

5.  Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019.

Authors:  Mee Joo Kang; E Hwa Yun; Kyu-Won Jung; Sang-Jae Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-07-29

6.  First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017.

Authors:  Mee Joo Kang; Jiwon Lim; Sung-Sik Han; Hyeong Min Park; Sang-Jae Park; Young-Joo Won; Sun-Whe Kim
Journal:  Cancer Res Treat       Date:  2021-05-21       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.